Uveitis Clinical Trial Pipeline Highlights 2019 - Forecast to 2024 by Clinical Stage, Drug Mechanism Classes, & Companies - ResearchAndMarkets.com

DUBLIN--()--The "Global Uveitis Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Uveitis Pipeline Highlights - 2019, provides the most up-to-date information on key pipeline products in the global uveitis market. It covers emerging therapies for uveitis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives in tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides uveitis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides uveitis pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides uveitis pipeline products by the company.

Short-term Launch Highlights:

Find out which uveitis pipeline products will be launched in the US and Ex-US to 2024.

Key Topics Covered:

1. Uveitis Pipeline by Stages

2. Uveitis Phase 3 Clinical Trial Insights

3. Uveitis Phase 2 Clinical Trial Insights

4. Uveitis Phase 1 Clinical Trial Insights

5. Uveitis Preclinical Research Insights

6. Uveitis Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/c8epuy

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Clinical Trials, Optical Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Clinical Trials, Optical Disorders Drugs